Open-label, Multi-centre, Parallel Group Dose-Escalation Trial Assessing the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2012
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2012 Planned End Date changed from 1 Feb 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.